Clinical classification of pulmonary hypertension.

[1]  P. Barnes,et al.  Chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[2]  S. Hodge,et al.  Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. , 2000, American journal of human genetics.

[3]  W. Seeger,et al.  Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled Trial , 2000, Annals of Internal Medicine.

[4]  Stuart Rich,et al.  Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.

[5]  M. Keszler,et al.  Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. , 2000, The New England journal of medicine.

[6]  E. Trulock,et al.  Worldwide thoracic organ transplantation: a report from the UNOS/ISHLT International Registry for Thoracic Organ Transplantation. , 2000, Clinical transplants.

[7]  G. Patterson,et al.  Lung transplantation: a decade of experience. , 1999, Annals of surgery.

[8]  M. Humbert,et al.  Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study , 1999 .

[9]  N. Voelkel,et al.  Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. , 1999, The Journal of clinical investigation.

[10]  S. Rich,et al.  Compassionate Use of Continuous Prostacyclin in the Management of Secondary Pulmonary Hypertension: A Case Series , 1999, Annals of Internal Medicine.

[11]  R. Barst,et al.  Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. , 1999, Circulation.

[12]  R. Whyte,et al.  Heart-lung transplantation for primary pulmonary hypertension. , 1999, The Annals of thoracic surgery.

[13]  G. Maislin,et al.  Vasodilator therapy for primary pulmonary hypertension in children. , 1999, Circulation.

[14]  K. Stenmark,et al.  Treatments for severe pulmonary hypertension , 1999, The Lancet.

[15]  A. Fishman.  Aminorex to fen/phen: an epidemic foretold. , 1999, Circulation.

[16]  M. Humbert,et al.  High-resolution CT of the chest in four patients with pulmonary capillary hemangiomatosis or pulmonary venoocclusive disease. , 1998, AJR. American journal of roentgenology.

[17]  M. Humbert,et al.  Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. , 1998, The European respiratory journal.

[18]  L. Sharples,et al.  Long term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension , 1998, Heart.

[19]  J. Sandoval,et al.  Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. , 1998, Journal of the American College of Cardiology.

[20]  M. Humbert,et al.  Treatment of severe pulmonary hypertension secondary to connective tissue diseases with continuous IV epoprostenol (prostacyclin). , 1998, Chest.

[21]  M. Humbert,et al.  Pulmonary vascular disorders in portal hypertension. , 1998, The European respiratory journal.

[22]  M. Humbert,et al.  Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. , 1998, American journal of respiratory and critical care medicine.

[23]  T. Higenbottam,et al.  Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost , 1998, Heart.

[24]  S. Rich,et al.  Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. , 1998, The New England journal of medicine.

[25]  L. Rubin,et al.  Primary pulmonary hypertension. , 1997, The New England journal of medicine.

[26]  H. Stricker,et al.  Prostacyclin for HIV-Associated Pulmonary Hypertension , 1997, Annals of Internal Medicine.

[27]  S. Hodge,et al.  Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32. , 1997, Circulation.

[28]  C. Howell,et al.  Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. , 1997, Transplantation.

[29]  S. Swensen,et al.  Pulmonary venoocclusive disease: CT findings in eight patients. , 1996, AJR. American journal of roentgenology.

[30]  J Benichou,et al.  Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. , 1996, The New England journal of medicine.

[31]  B. Groves,et al.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.

[32]  W. Summer,et al.  Effect of prostacyclin on microvascular pressures in a patient with pulmonary veno-occlusive disease. , 1995, Chest.

[33]  P. Dartevelle,et al.  [Pulmonary arterial hypertension of chronic thromboembolic origin; therapeutic indications]. , 1994, Archives des maladies du coeur et des vaisseaux.

[34]  R. Barst,et al.  Survival in Primary Pulmonary Hypertension with Long-Term Continuous Intravenous Prostacyclin , 1994, Annals of Internal Medicine.

[35]  M. Dolgin,et al.  Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels , 1994 .

[36]  H. Winer-Muram,et al.  Pulmonary capillary hemangiomatosis: a clinicopathologic review. , 1994, The Annals of thoracic surgery.

[37]  G. Pietra.  Histopathology of primary pulmonary hypertension. , 1994, Chest.

[38]  S. Rich,et al.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. , 1992, The New England journal of medicine.

[39]  W. Auger,et al.  Chronic thromboembolic pulmonary hypertension: clinical picture and surgical treatment. , 1992, The European respiratory journal.

[40]  T. Higenbottam,et al.  Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension , 1991, The Lancet.

[41]  D. Greenberg.  THE PULMONARY CIRCULATION: NORMAL AND ABNORMAL , 1991 .

[42]  W. Edwards.  Plexogenic pulmonary arteriopathy , 1990, Histopathology.

[43]  J. H. Diehl,et al.  Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol): Results of a Randomized Trial , 1990 .

[44]  S. Hunt,et al.  Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. , 1982, The New England journal of medicine.

[45]  K. Peterson,et al.  Modifications of techniques and early results of pulmonary thromboendarterectomy for chronic pulmonary embolism. , 1987, The Journal of thoracic and cardiovascular surgery.

[46]  E. Shinebourne,et al.  Effect of long term oxygen treatment at home in children with pulmonary vascular disease. , 1986, British heart journal.

[47]  E. Weitzenblum,et al.  Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. , 1985, The American review of respiratory disease.

[48]  F. Khaja,et al.  Hemodynamic response to oxygen therapy in chronic obstructive pulmonary disease. , 1985, Annals of internal medicine.

[49]  V. Fuster,et al.  Primary pulmonary hypertension: natural history and the importance of thrombosis. , 1984, Circulation.

[50]  T. Higenbottam,et al.  LONG-TERM TREATMENT OF PRIMARY PULMONARY HYPERTENSION WITH CONTINUOUS INTRAVENOUS EPOPROSTENOL (PROSTACYCLIN) , 1984, The Lancet.

[51]  B. Groves,et al.  Prostacyclin‐induced Acute Pulmonary Vasodilation in Primary Pulmonary Hypertension , 1982, Circulation.

[52]  W. Edwards,et al.  Clinical primary pulmonary hypertension: three pathologic types. , 1977, Circulation.

[53]  J. Shaver,et al.  Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). , 1977, Annals of internal medicine.

[54]  A. Fishman.  Dietary Pulmonary Hypertension , 1974, Circulation research.

[55]  E. Dailey,et al.  Pulmonary thromboembolic disease. A lobular concept. , 1972, Radiology.

[56]  J. Edwards,et al.  The Pathology of Hypertensive Pulmonary Vascular Disease: A Description of Six Grades of Structural Changes in the Pulmonary Arteries with Special Reference to Congenital Cardiac Septal Defects , 1958, Circulation.

[57]  John Rose Bradford,et al.  The Pulmonary Circulation 1 , 1894 .

[58]  W. Ingalls.  A Case of Fracture of the Spleen, and Rupture of the Intestines, Occasioned by External Violence , 1828 .